Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk

被引:38
|
作者
Blanco-Colio, Luis M. [1 ]
Martin-Ventura, Jose L. [1 ]
Gomez-Guerrero, Cannen [1 ]
Masramon, Xavier [2 ]
de Teresa, Eduardo [3 ,4 ]
Farsang, Csaba [5 ]
Gaw, Allan [6 ]
Gensini, GianFranco [7 ]
Leiter, Lawrence A. [8 ,9 ]
Langer, Anatoly [8 ,9 ,10 ]
Egido, Jesus [1 ]
机构
[1] Univ Autonoma Madrid, Fdn Jimenez Diaz, Vasc Res Lab, E-28040 Madrid, Spain
[2] European Biometr Inst, Barcelona, Spain
[3] Univ Malaga, E-29071 Malaga, Spain
[4] Victoria Hosp, Malaga, Spain
[5] Semmelweis Univ, Dept Med 1, H-1085 Budapest, Hungary
[6] Univ Glasgow, Glasgow, Lanark, Scotland
[7] Univ Florence, Careggi Hosp, Florence, Italy
[8] Univ Toronto, Toronto, ON, Canada
[9] St Michaels Hosp, Toronto, ON M5B 1W8, Canada
[10] Canadian Heart Res Ctr, Toronto, ON, Canada
关键词
cholesterol-lowering drugs; high cardiovascular risk; inflammation; adiponectin;
D O I
10.1016/j.ejphar.2008.02.042
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Adiponectin can suppress atherogenesis by inhibiting the adherence of monocytes, reducing their phagocytic activity, and suppressing the accumulation of modified lipoproteins in the vascular wall. Contradictory data have been reported about the effect of statins on adiponectin plasma levels. In this work, adiponectin plasma levels were measured in 102 statin-free subjects from the Spanish population of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study, a 12-week, prospective, multi-centre, open-label trial which enrolled subjects with coronary heart disease, coronary heart disease-equivalent or a 10-year coronary heart disease risk > 20%. Subjects were assigned to atorvastatin (10-80 mg/day) based on low-density lipoprotein (LDL)-cholesterol concentration at screening. For comparison, age and gender-matched blood donors (N=40) were used as controls. Control subjects did not present hypertension, hypercholesterolemia, diabetes, metabolic syndrome and history of cardiovascular diseases. Adiponectin levels were diminished in patients at high cardiovascular risk compared with control subjects [4166 (3661-4740) vs 5806 (4764-7075) ng/ml respectively; geometric mean (95% CI); P < 0.0001]. In the whole population, atorvastatin treatment increased adiponectin levels [9.7 (3.2-16.7);% Change (95% CI); P=0.003]. This increment was in a dose-dependent manner; maximal effect observed with atorvastatin 80 mg/d [24.7 (5.7-47.1); P=0.01]. Adiponectin concentrations were positively correlated with high-density lipoprotein-cholesterol both before and after atorvastatin treatment. No association was observed between adiponectin and LDL-cholesterol before and after atorvastatin treatment. In conclusion, atorvastatin increased adiponectin plasma levels in subjects at high cardiovascular risk, revealing a novel anti-inflammatory effect of this drug. (c) 2008 Elsevier B.V. All rights reserved.
引用
收藏
页码:259 / 265
页数:7
相关论文
共 50 条
  • [1] Increased soluble Fas plasma levels in subjects at high cardiovascular risk -: Atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST
    Blanco-Colio, Luis M.
    Martin-Ventura, Jose L.
    de Teresa, Eduardo
    Farsang, Csaba
    Gaw, Allan
    Gensini, GianFranco
    Leiter, Lawrence A.
    Langer, Anatoly
    Martineau, Pierre
    Hernandez, Gonzalo
    Egido, Jesus
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (01) : 168 - 174
  • [2] Increased soluble Fas Plasma Levels in subjects at High Cardiovascular Risk. Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST
    Martinez Gonzalez, Jose
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2007, 19 (04): : 213 - 214
  • [3] Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk
    Gonbert, S
    Malinsky, S
    Sposito, AC
    Laouenan, H
    Doucet, C
    Chapman, MJ
    Thillet, J
    ATHEROSCLEROSIS, 2002, 164 (02) : 305 - 311
  • [4] Several metabolic risk factors in subjects with increased plasma adiponectin levels: Causality of positive associations
    Kawada, Tomoyuki
    HEART & LUNG, 2016, 45 (03): : 295 - 295
  • [5] Atorvastatin diminished ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers (AIM) study
    Blanco-Colio, L. M.
    Martin-Ventura, J. L.
    De Teresa, E.
    Farsang, C.
    Gaw, A.
    Gensini, G. F.
    Leiter, L. A.
    Langer, A.
    Martineau, P.
    Egido, J.
    ATHEROSCLEROSIS SUPPLEMENTS, 2006, 7 (03) : 572 - 572
  • [6] High Prevalence of Metabolic Syndrome in Takayasu Arteritis: Increased Cardiovascular Risk and Lower Adiponectin Serum Levels
    da Silva, Thiago Ferreira
    Levy-Neto, Mouricio
    Bonfa, Eloisa
    Pereira, Rosa Maria R.
    JOURNAL OF RHEUMATOLOGY, 2013, 40 (11) : 1897 - 1904
  • [7] High Prevalence Of Metabolic Syndrome In Takayasu Arteritis: An Increased Cardiovascular Risk and Lower Adiponectin Serum Levels
    Silva, Thiago
    Levy-Neto, Mauricio
    Pereira, Rosa M. R.
    Bonfa, Eloisa
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S712 - S713
  • [8] Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer
    Otake, Sayaka
    Takeda, Hiroaki
    Fujishima, Shoichiro
    Fukui, Tadahisa
    Orii, Tomohiko
    Sato, Takeshi
    Sasaki, Yu
    Nishise, Shoichi
    Kawata, Sumio
    WORLD JOURNAL OF GASTROENTEROLOGY, 2010, 16 (10) : 1252 - 1257
  • [9] PLASMA ADIPONECTIN LEVELS FOR PREDICTION OF CARDIOVASCULAR RISK AMONG HEMODIALYSIS PATIENTS
    El-Shafey, Eid
    Ezaat, Amal
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 : 235 - 235
  • [10] Plasma Adiponectin Levels for Prediction of Cardiovascular Risk Among Hemodialysis Patients
    El-Shafey, Eid M.
    Shalan, Mohamed
    THERAPEUTIC APHERESIS AND DIALYSIS, 2014, 18 (02) : 185 - 192